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Objectives: We aimed to determine the demographic characteristics of giant cell tumor around the knee
in China.
Methods: Between March 2000 and June 2014, patients with primary giant cell tumor around the knee
were recruited from 6 institutions located in different regions of China, and were reviewed retro-
spectively the clinical features according to gender and age.
Results: 334 qualiﬁed patients were included in this study. The sex ratio was 1.14:1 (178/156), with mean
ages of 36.9 years in men and 33.1 years in women, constituting a signiﬁcant difference (P¼0.007). The
prevalence of pathological fracture was 32.9% overall (28.7% in men and 37.8% in women). The prevalence
of simple fracture was signiﬁcantly higher in women (26.3%) than in men (15.2%), P¼0.042. Tumor lo-
cation and staging did not differ signiﬁcantly according to sex (P40.05). However, comparing with 440
years old, those patients aged r40 were more likely to have a right knee tumor (56.7% vs. 44.7%,
P¼0.042), less likely to have Enneking stage 3 disease (18.6% vs. 35.0%, P¼0.005), and less likely to have
both soft-tissue extension and a mass (18.6% vs. 34.0%, P¼0.009).
Conclusions: Giant cell tumor around the knee was more common in men than in women, although
female patients were younger on average. Further, cases among patients r40 years old were observed to
be milder than cases among older patients. The results suggest that efﬁcient treatment and preservation
of function should both be valued for young patients with giant cell tumor around the knee.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Giant cell tumor (GCT) is a primary intramedullary bone tumor that
is composed of mononuclear and giant mononuclear cells, resembling
osteoclasts [1]. It usually involves the end of a long bone. The World
Health Organization has classiﬁed GCT as an aggressive, potentiallyGmbH. This is an open access artmalignant lesion [2]. GCT accounts for 3–8% of primary bone tumors in
Western nations, but it is more common in Asia, accounting for 20% of
primary bone tumors [3–8]. GCT is most commonly diagnosed among
20–40 year olds, more likely to locate many sites of body, but half of
GCTs occur around the knee [3,4,9–12]. About 10% of GCTs undergo
malignant transformation, and pulmonary metastases occur in 1% to 4%
of cases [13]. It has been reported that the postoperative recurrence rate
is 10%–65% [5,6,14–16]. Therefore, GCT is one of the most controversial
and widely discussed bone tumors [1,17,18].icle under the CC BY-NC-ND license
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have indicated that GCTs predominantly occur among women,
with a male-to-female gender ratio of 0.8:1 [5,19,20]. However,
some studies have not shown this predominance [1,17,18]. Further,
other studies have shown that most cases in Asia occur in men,
with a gender ratio of 1.27–1.77 [21–24].
Recently, several studies from one institution have documented
the characteristics of GCT in China. However, there has been an
absence of large, multicenters, and representative studies of pa-
tients with GCT in China. In this study, we recruited the GCT pa-
tients from The Giant cell tumor Team of China, a multicenter
nationwide GCT registry system, to explore the epidemiological
characteristics of primary GCT around the knee, focusing on im-
proving its diagnosis and treatment in China.2. Materials and methods
2.1. Patients' selection
Between March 2000 and July 2014, patients with primary GCT
around the knee were recruited from this multicenter nationwide
GCT registry system, which included 6 centers of Orthopedic On-
cology from different regions in China: Tianjin, Shandong, Shanxi,
Zhejiang, Jiangsu, and Inner Mongolia. All patients had received
their ﬁrst histologically conﬁrmed diagnoses of benign GCT and
underwent surgical treatment. We excluded all patients with a
preoperative diagnosis of GCT that was postoperatively de-
termined to have been incorrect (i.e., patients with a non-GCT
postoperative diagnosis). We further excluded all cases of GCT
recurrence and all patients who were not treated surgically. Clin-
ical and imaging data of the primary GCTs around the knee were
reviewed retrospectively.
The ethics committee of Tianjin Hospital approved the study,
and written informed consent was obtained from all patients
during recruitment.
2.2. Tumor location
The patients with primary GCT around the knee were classiﬁed
in three ways, according to the locations of their tumors. The ﬁrst
method of classifying location included the distal femur, proximal
tibia, and other sites (the ﬁbula and patella). The second method of
classifying the tumor provided information on laterality (whether
the tumor was located in the left or right knee). In the third
method of grouping the tumors, tumors were classiﬁed as having
grown centrically or eccentrically.
2.3. Staging
GCT is staged according to the Enneking staging system for
benign bone tumors [25]. Under this system, stage 1(T0) includes
latent lesions that are biologically static; stage 2(T1) includes ac-
tive, slow-growing lesions that are conﬁned within the bone; and
stage 3(T2) includes locally aggressive lesions with soft-tissue ex-
tension. GCTs can also be stratiﬁed according to the Campanacci
system, which is based on plain radiography [26]. Under the
Campanacci system grade I are the least common, and show fea-
tures of latent or slow-growing tumors. The lesion is small, with a
mild amount of sclerosis delineating the tumor. Bone contour is
not affected, although the cortex can be thinned. The tumor does
not extend to the articular cartilage. Symptoms are absent or
minimal and of long duration. Grade II show features of an active
lesion with ill-deﬁned borders and without sclerosis. The cortex is
thinned, if not breached and deformed with expansion, and the
periosteum is elevated. The tumor often extends to the articularcartilage from within the marrow. Grade III show features of ex-
treme aggressiveness, with a tumor that has a large volume, de-
stroys bone, and invades the surrounding soft tissues.
2.4. Soft-tissue extension and mass
Depending upon whether soft-tissue extension and/or mass
were present, all patients were divided into 3 groups: patients
with neither soft-tissue extension nor mass, patients with soft-
tissue extension alone, and patients with both soft-tissue exten-
sion and mass.
2.5. Pathologic fracture
Pathologic fracture was conﬁrmed based on radiological and
surgical data. The types of pathologic fracture included (i) the
absence of any pathological fracture, (ii) simple pathological
fracture, and (iii) complex pathological fracture. Simple patholo-
gical fracture was deﬁned as the presence of pathological fractures
located extra-articular, or the presence of intra-articular fracture
with a complete articular surface, no or mild shifting, a gross tu-
mor volume o200 cm3, a distance of 43 mm between the tumor
and subchondral bone, and no soft-tissue extension or mass.
Complex pathological fracture was deﬁned as the presence of
pathological fractures located in the intra-articular with a de-
structive articular surface, obvious shifting, a gross tumor volume
4200 cm3, a distance of o4 mm between the tumor and sub-
chondral bone, and soft-tissue extension and mass.
2.6. Surgical treatment
Surgical techniques were based on the severity of the tumor
and included intralesional curettage, curettage combined with
resection, and en bloc marginal resection [27].
Intralesional curettage was indicated for patients with a loca-
lized lesion. With this procedure, a window in the cortical bone is
made, followed by resection of the mass using a series of curettes
of various sizes; the residual tumor cavity is then polished with a
high-speed burr until the normal cortical bone is reached and is
ﬁlled with allogeneic particle bone graft to ﬁll the window.
Curettage combined with resection was performed in patients
with an extensive lesion. With this procedure, the cortical bone
and soft tissue mass impossible reserved are removed, and the
tumor cavity is disposed using curettes and a high-speed burr;
cavitary bone defects are then ﬁlled with allogeneic particle bone
graft, and an anatomical bone plate is used for internal ﬁxation.
En bloc marginal resection was indicated for patients with se-
vere involvement lesions. With this procedure, an osteotomy plane
is conﬁrmed based on preoperative magnetic resonance imaging,
and the tumor is resected en bloc; an articulated prosthesis is used
to reconstruct the knee.
2.7. Follow-up and outcome
The patients were followed-up every 3 months for the ﬁrst
2 years post-operation, every 6 months until 5 years post-opera-
tion, and every 12 months until 10 years post-operation. Tele-
phone interviews were allowed only after 5 years of follow-up.
Information of local recurrence and metastases was obtained by
face-to-face interview or telephone follow-up.
2.8. Statistical methods
All patient data were analyzed according to gender and age
group. Because cases of GCT most commonly occur among patients
20–40 years old, age was categorized to two groups: r40 years
Table 2
The clinical characteristics of primary GCT around the knee by gender in China.
Categories Male Female Total P
Location 1, n (%) 0.369
Distal femur 93 (52.2) 82 (52.6) 175 (52.4)
Proximal tibia 75 (42.1) 70 (44.9) 145 (43.4)
F. Lin et al. / Journal of Bone Oncology 5 (2016) 38–4240and 440 years. Continuous variables were summarized in terms
of means (standard deviations) and categorical variables were
summarized in terms of case numbers (percentages). The chi-
square test was used to assess differences between the clinical and
radiological characteristics of different gender and age groups.
Differences in age were compared using the t-test. Statistical sig-
niﬁcance was deﬁned as Po0.05.Others 10 (5.6) 4 (2.6) 14 (4.2)
Location 2, n (%) 0.770
Left knee 85 (47.8) 72 (46.2) 157 (47.0)
Right knee 93 (52.2) 84 (53.8) 177 (53.0)
Location 3, n (%) 0.544
Non-centricity growth 136 (81.0) 127 (83.6) 273 (82.2)
Centricity growth 32 (19.0) 25 (16.4) 57 (17.8)
Campanacci grade, n (%) 0.496
I 23 (12.9) 14 (9.0) 37 (11.1)
II 77 (43.3) 73 (46.8) 150 (44.9)
III 78 (43.8) 69 (44.2) 147 (44.0)
Ennecking stage, n (%) 0.741
T0 77 (43.3) 61 (39.1) 138 (41.3)
T1 60 (33.7) 57 (36.5) 117 (35.0)
T2 41 (23.0) 38 (24.4) 79 (23.7)
Soft tissue extension and mass 0.437
None of them 63 (35.4) 55 (35.3) 118 (35.3)
Soft tissue extension without mass 78 (43.8) 60 (38.5) 138 (41.3)
Both of them 37 (20.8) 41 (26.3) 78 (23.4)
Type of pathologic fracture, n (%) 0.042
No 127 (71.3) 97 (62.2) 224 (67.1)
Simple 27 (15.2) 41 (26.3) 68 (20.4)
Complex 24 (13.5) 18 (11.5) 42 (12.6)
Surgical treatment, n (%) 0.616
Intralesional curettage 40 (22.6) 37 (23.7) 77 (23.1)
Curettage combined with
resection
93 (52.6) 75 (47.5) 168 (50.3)
En bloc marginal resection 44 (24.9) 45 (28.8) 89 (26.6)
Table 3
The clinical characteristics of primary GCT around the knee by age in China.
Categories r40 years 440 years Total P
Location 1, n (%) 0.086
Distal femur 115 (49.8) 60 (58.3) 175 (52.4)
Proximal tibia 103 (44.6) 42 (40.8) 145 (43.4)
Others 13 (5.6) 1 (1.0) 14 (4.2)
Location 2, n (%) 0.042
Left knee 100 (43.3) 57 (55.3) 157 (47.0)
Right knee 131 (56.7) 46 (44.7) 177 (53.0)
Location 3, n (%) 0.067
Non-centricity growth 184 (84.4) 79 (77.5) 263 (82.2)
Centricity growth 34 (15.6) 23 (22.5) 57 (17.8)
Campanacci grade, n (%) 0.9233. Results
3.1. Demographic characteristics
Of the 334 patients with primary GCT around the knee, 178
were men and 156 were women, amounting to a sex ratio of 1.14:1.
The mean ages of ﬁrst diagnosis with GCT were 35.1 years overall,
there was a signiﬁcantly younger mean age of diagnosis in women
than in men (33.1 vs. 36.9 years), P¼0.007 (Table 1).
3.2. Location
Tables 2 and 3 showed than there were no signiﬁcant gender
differences in tumor location (P40.05). But there was more le-
sions located in the right knee in r40-years-old patients than in
440-year-old patients (56.7% vs. 44.7%, P¼0.042). (Table 3).
3.3. Tumor staging
There were no remarkable gender differences in Campanacci
grades and Enneking stages (Table 2). However, patients r40-
year-olds were less likely to have Enneking T2, as compared with
patients 440-year-olds (18.6% vs. 35.0%), P¼0.005 (Table 3).
3.4. The style of soft-tissue extension and mass
Table 2 presented that there was not signiﬁcant gender differ-
ence in the style of soft-tissue extension and mass. The proportion
of patients with both soft-tissue extension and mass was higher
among 440-year-olds than among r40-year-olds (34.0% vs.
18.6%), P¼0.009 (Table 3).
3.5. Pathological fracture
The prevalence of pathological fracture in patients with pri-
mary GCT around the knee was 32.9% overall. The prevalence of
simple pathological fracture was signiﬁcantly lower in men than in
women (15.2% vs. 26.3%), P¼0.042 (Tables 2 and 3).Table 1
The demographical characteristics of primary GCT around the knee in China.
Categories Male Female Total P
Number, n (%) 178 (53.3) 158 (46.7) 334 (100) –
Age, year, means(SD) 36.9 (13.5) 33.1 (12.1) 35.1 (13.0) 0.007
Age group, n (%) 0.118
o20 10 (5.6) 13 (8.3) 23 (6.9)
20 53 (29.8) 65 (41.7) 118 (35.3)
30 48 (27.0) 31 (19.9) 79 (23.7)
40 37 (20.8) 26 (16.7) 63 (18.9)
Z50 30 (16.9) 21 (13.5) 51 (15.3)
Center, n (%) 0.831
Tianjin 34 (51.5) 32 (48.5) 66 (19.8)
Shandong 34 (61.8) 21 (46.6) 55 (16.5)
Xian 47 (53.4) 41 (46.6) 88 (26.3)
Jiangsu 18 (51.4) 17 (48.6) 35 (10.5)
Zhejiang 36 (50.0) 36 (50.0) 72 (21.6)
Inner Mongu 9 (50.0) 9 (50.0) 18 (5.4)
I 26 (11.3) 11 (10.7) 37 (11.1)
II 105 (45.5) 45 (43.7) 150 (44.9)
III 100 (43.3) 47 (45.6) 147 (44.0)
Ennecking stage, n (%) 0.005
T0 103 (44.6) 35 (34.0) 138 (41.3)
T1 85 (36.8) 32 (31.1) 117 (35.0)
T2 43 (18.6) 36 (35.0) 79 (23.7)
Soft tissue extension and mass 0.009
None of them 86 (37.2) 32 (31.1) 118 (35.3)
Soft tissue extension without
mass
102 (44.2) 36 (35.0) 138 (41.3)
Both of them 43 (18.6) 35 (34.0) 78 (23.4)
Pathologic fracture, n (%) 0.756
No 157 (68.0) 67 (65.0) 224 (67.1)
Simple 47 (20.3) 21 (20.4) 68 (20.4)
Complex 27 (11.7) 15 (14.6) 42 (12.6)
Surgical treatment, n (%) 0.021
Intralesional curettage 60 (26.1) 17 (16.5) 77 (23.1)
Curettage combined with
resection
118 (22.6) 50 (47.6) 168 (50.3)
En bloc marginal resection 52 (22.6) 37 (35.9) 89 (26.6)
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There were higher frequency of En bloc marginal resection in
patients aged 40 years and older than in patients aged o40 years,
with the rate of 35.9% and 22.6% (P¼0.013), respectively (Table 3).
3.7. Outcomes
Total 268 were qualiﬁed for follow-up, with a median follow-
up time of 55 months (range, 12–188 months). Of these patients,
215 patients completed Z12 months of follow-up, with a re-
sponding rate of 80.2% in this study. The local recurrence rate was
21.4% overall, 24.3% in men, and 18.3% in women; no signiﬁcant
difference in local recurrence rate was found between genders
(P¼0.279). Similar trends were observed for age group, with a
local recurrence rate of 24.5% in those aged r40-year-olds and
14.7% in those aged 440-year-olds (P¼0.104).
Among the patients with at least 12 months of follow-up, there
were 3 patients with metastasis, including two cases of pulmonary
metastasis and one case of thoracic vertebra metastasis. The pul-
monary metastasis rate of GCTs around the knee was 0.9%, while
the overall metastasis rate of GCTs around the knee was 1.4%.4. Discussion
The incidence rates and gender distributions of GCT have be-
come issues of contention for researchers around the world. In a
study in the US city of Philadelphia, it was determined that GCT
accounts for 5–7% of all primary bone tumors, yet it has also been
reported that GCT accounts for 30% of primary bone tumors in
south India [22]. In Western nations, GCT is more likely to occur in
women than in men; one study has reported that 48.5% of cases
occur in men and 51.5% occur in women [20], while another study
has reported that 44% of cases occur in men and 56% occur in
women [28]. However, several studies have reported that GCT
predominately occurs in men, with a male-to-female gender ratio
of 1.27–1.77 [7,21–23]. Consistent with these studies, we also
found that ﬁrst GCT around the knee predominantly occurred in
men, with a gender ratio of 1.14:1 in the present study.
Most studies have indicated that GCT usually occurs in young
adults aged 20–40 years, accounting for 70–80% of all cases, and
that few cases occur after epiphysis clogging [20,28]. In the pre-
sent study, 77.8% patients with primary GCT around the knee were
diagnosed at the age between 20–40 years. Moreover, we found
that ﬁrst GCT around the knee was diagnosed at a younger average
age in women than in men; this may be explained by earlier
epiphysis clogging in women.
Studies of the laterality of GCTs of the knee are rare, though all
studies have conﬁrmed that the knee is the joint that is the most
common site for this disease, accounting for 50–70% of cases [6,7].
In this study, a higher prevalence of ﬁrst GCT was observed for the
right knee in the group of patients r40 years of age. This may
partly be explained by dextrality and heavy load bearing in young
adults. The prevalence of eccentric growth was dominant in this
study, a ﬁnding that is consistent with previous studies [7].
Campanacci et al. reported that only 10–15% of GCTs belong to
grade I [29]. The most common grades were II and III, accounting
for 70–80% and 20% of cases, respectively [28]. In contrast with
these previous studies, we found similar prevalence rates of grade
II (44.9%) and grade III (44.0%) disease in the present study. In
several studies, it has been reported that grade III has a high re-
currence rate [6,26,30]. However, results from China suggest
higher recurrence of GCT with Campanacci grade II [7]. Thus,
treatment of GCT should simultaneously focus on local control and
the maintenance of function. We found a greater prevalence ofEnneking stage T2 stage in patients aged 440 years (35.0%) than
in patients aged r40 years (18.6%).
The GCT usually involves a cladding that consisted of reactive
bone and ﬁbrosis, with a distinct boundary surrounded by soft
tissue. Nevertheless, the active cladding is very thin among pa-
tients with severe invasiveness, including tumors that extend di-
rectly in into the muscle and fat, or other signs. Moreover, the
tumor can be involved in synovial tissue, joint capsules, ligaments,
and muscle tendons. It can even extend the contralateral bone
along with soft tissue. Therefore, the assessment of soft-tissue
extension is very important to guide clinical treatment. Moreover,
soft-tissue extension has been found to increase the risk of local
recurrence [2].
We found that more than one-third of patients aged 440 years
at their ﬁrst GCT diagnosis had both tumor and soft-tissue
extension.
GCT is an osteolytic lesion. The bone cortex tends to attenuate
because it has been invaded by tumor, rupture because of stress or
an exogenous process, and then form a pathological fracture. Pa-
thological fracture is found in 9–30% of patients with GCT [30]. It
has been reported that 15% of GCT patients have the ﬁrst symp-
toms of pathological fracture [3,31]. A previous study reported that
pathologic fractures were associated with increased recurrence
rates [26].
The prevalence of pathological fracture was 32.9% in this study,
and a signiﬁcantly higher prevalence of simple fracture was ob-
served in women (26.3%) than in men (15.2%). This sex difference
may be partly explained by the lower weights of bones in women
than in men. Indeed, we observed that the female patients were
more likely to have thin cortex of bone, lower bone mineral den-
sity, and few bone trabeculae. Moreover, the pulmonary metastasis
rate of GCTs around the knee was 0.7%, while the overall metas-
tasis rate was 1.3%, lower than rates reported previously [6,7].
There are limitations to this study. Most notably, this is a
multicenter retrospective study, and there may have been differ-
ences between the identiﬁcation standards in radiological data
and the clinical staging at different institutions. However, this
could be overcome by training the investigators from the 6 cen-
ters. Moreover, all patients were recruited from 2000 to 2014; new
techniques were not developed during this 15-year period, and the
standard of diagnosis did not change.5. Conclusion
This is the ﬁrst report of the epidemiological characteristics
primary GCT on clinical and radiological features around the knee
in China, as analyzed according to gender and age group, and as
based on a large, multicenter, and nationwide sample. Our results
validate previous ﬁndings, including the male preponderance of
GCT, its more frequent occurrence at ages 20–40, the overall fre-
quency of its occurrence around the knee. Moreover, we have
provided several new discoveries: women are diagnosed at
younger average ages and have a greater prevalence of simple
pathological fracture than do men. Further, young patients have a
tendency towards right knee preponderance. However, the disease
is generally milder among young patients. These results suggest
that surgeons should emphasize both the risk of local recurrence
and the preservation of joint function for young and female
patients.Ethical approval
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